Health tracking and analytics platform Tictrac has partnered with Novartis to launch an awareness campaign, called The 7-Day Challenge to Live Like You, for multiple sclerosis (MS). "MS is a ...
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...
-- Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) ...
Novartis today announced full results from the positive Phase III PARADIGMS study, investigating the safety and efficacy of Gilenya ® (fingolimod) vs. interferon beta-1a, in children and adolescents ...
Basel, Switzerland-based pharmaceutical company Novartis and Seattle-based research nonprofit Sage Bionetworks initiated a large-scale study on multiple sclerosis using the Apple ResearchKit software ...
Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia. It’s the first time a pharma ...
Novartis won approval for its multiple sclerosis drug Mayzent, which will launch at a price of $88,000 annually, according to Reuters. 1. Mayzent, an oral drug, was approved for adults with relapsing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback